NexACT works as an anti-microbial preservative, says Apricus Bio
The results show the US drug delivery specialist’s NexACT technology is capable of killing over 23 different strains of bacteria, fungus and mold, exceeding all requirements for passing the USP PET.
Bassam Damaj, president and CEO of Apricus Bio, commented: “The safety of NexACT has been tested extensively in over 4,500 patients to date, with excellent results.” This places the technology in good stead to compete with other commonly used preservatives, such as parabens.
“The ability of NexACT to function as a preservative opens up new partnering opportunities with pharmaceutical and cosmetic developers,” he added.
Earlier this year, Apricus Bio received $2.7m (€2.0m) in development funding for NexACT from two US investors, and have since signed a distribution deal with Cosmo Bio to market products based on NexACT technology in Japan.
